molecular pathology

Molecular Pathology involves the study of genes and alterations in genes in human cells.

The molecular pathology laboratory at MetroPath employs a wide variety of techniques to study DNA and RNA isolated from clinical samples. The high sensitivity and specificity of these tests allows for rapid, accurate detection and identification of infectious microorganisms and for the detection of genetic abnormalities in human cells.

MetroPath offers comprehensive screening for a wide variety of infectious organisms affecting women and their partners. These tests are preferentially performed on highly automated, FDA approved platforms using a variety of clinical specimens (ThinPrep®and SurePath™ cytology, endocervical and urethral swabs, and urine). Real-time polymerase chain reaction (PCR) technique is utilized to detect a wide variety of viral, bacterial, and fungal microorganisms that can infect the urogenital tract of men and women. Most of these tests can be performed from one patient sample, removing the need for multiple specimen collections.

Fluorescence in situ hybridization (FISH) tests can detect genetic abnormalities found in cancer cells. These results often confirm the diagnosis of cancer, determine response to therapy, and/or aid in assessing the prognosis for individual patients.

Molecular pathology tests:

  • High risk HPV testing with HPV Type 16 and 18 genotyping, performed alone or in conjunction with cervical cytology
  • Prenatal Group B Streptococcus molecular testing, in full compliance with CDC and ACOG guidelines
  • Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis
  • Herpes Simplex Virus, Type I and II
  • Comprehensive Bacterial Vaginosis Panel
  • Candida species, Ureaplasma urealyticum, and Mycoplasma hominis

Pathology-interpreted tests:

  • Her2 amplification status by FISH in invasive breast cancer
  • Urovysion FISH for detection of bladder cancer in urine cytology specimens
  • Cervical DNA Dtex for detection of irreversible genetic abnormalities

Our services include:

  • Custom test panels
  • 1-2 business day turnaround for most tests
  • Consultation with pathologists to aid in test interpretation and other inquiries
  • Access to reference laboratory for additional esoteric tests


If you have any questions about MetroPath’s Molecular Pathology services, please feel free to contact us.

Director of Molecular Pathology – Mirna Z. Knight, D.O., Ph.D.